BiomX Inc. 8-K Summary: Special Meeting Results
Business Context and Reporting Period
This Form 8-K reports the results of a Special Meeting of Stockholders held by BiomX Inc. on August 25, 2026. The meeting was conducted virtually. As of the record date (August 10, 2026), there were 26,559,607 shares of common stock outstanding. A total of 9,813,430 shares (approximately 36.9%) were represented at the meeting, constituting a quorum.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and stockholder voting results.
Material Changes and Voting Results
Stockholders approved four key proposals:
- Proposal 1 (Issuance Approval): Approved the issuance of common stock and convertible securities to Mandragola Ltd. in connection with the acquisition of controlling equity interests in Dr. Frucht Systems Ltd. This includes shares for a Line of Credit and potential Revenue Bonus satisfaction.
- For: 9,313,228
- Against: 429,645
- Abstain: 70,557
- Proposal 2 (Reverse Split): Approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-20, to be determined by the Board within one year. If implemented, authorized shares will be reduced from 750,000,000 to 150,000,000.
- For: 9,293,937
- Against: 453,526
- Abstain: 65,967
- Proposal 3 (Auditor Ratification): Ratified the appointment of Barzily & Co. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- For: 9,575,900
- Against: 176,487
- Abstain: 61,043
- Proposal 4 (Adjournment): Approved the ability to adjourn the meeting to solicit additional proxies if necessary. No adjournment was required as Proposals 1, 2, and 3 were approved.
- For: 9,529,079
- Against: 237,990
- Abstain: 46,361
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the voting outcomes. The approval of the reverse split indicates a strategic move to adjust the share structure, potentially to meet listing requirements or improve market perception, though the exact timing and ratio remain at the Board's discretion.
Investor Verification Checklist
- Verify the final implementation date and specific ratio of the reverse stock split (1-for-5 to 1-for-20).
- Review the definitive agreement regarding the acquisition of Dr. Frucht Systems Ltd. and the terms of the Line of Credit with Mandragola Ltd.
- Confirm the reduction of authorized shares from 750 million to 150 million upon execution of the reverse split.
- Monitor future filings for the actual issuance of shares to Mandragola Ltd. and any impact on dilution.